Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 9.58
ICLR's Cash to Debt is ranked higher than
74% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. ICLR: 9.58 )
ICLR' s 10-Year Cash to Debt Range
Min: 0.85   Max: No Debt
Current: 9.58

Equity to Asset 0.62
ICLR's Equity to Asset is ranked higher than
72% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ICLR: 0.62 )
ICLR' s 10-Year Equity to Asset Range
Min: 0.53   Max: 0.77
Current: 0.62

0.53
0.77
Interest Coverage 257.77
ICLR's Interest Coverage is ranked higher than
69% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 566.16 vs. ICLR: 257.77 )
ICLR' s 10-Year Interest Coverage Range
Min: 17.93   Max: 382.53
Current: 257.77

17.93
382.53
F-Score: 7
Z-Score: 6.23
M-Score: -2.31
WACC vs ROIC
7.14%
25.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.66
ICLR's Operating margin (%) is ranked higher than
92% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. ICLR: 14.66 )
ICLR' s 10-Year Operating margin (%) Range
Min: 3.11   Max: 13.46
Current: 14.66

3.11
13.46
Net-margin (%) 12.46
ICLR's Net-margin (%) is ranked higher than
93% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. ICLR: 12.46 )
ICLR' s 10-Year Net-margin (%) Range
Min: 2.42   Max: 13.44
Current: 12.46

2.42
13.44
ROE (%) 19.53
ICLR's ROE (%) is ranked higher than
94% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. ICLR: 19.53 )
ICLR' s 10-Year ROE (%) Range
Min: 3.39   Max: 18.54
Current: 19.53

3.39
18.54
ROA (%) 12.45
ICLR's ROA (%) is ranked higher than
94% of the 302 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.41 vs. ICLR: 12.45 )
ICLR' s 10-Year ROA (%) Range
Min: 2.31   Max: 11.61
Current: 12.45

2.31
11.61
ROC (Joel Greenblatt) (%) 98.61
ICLR's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. ICLR: 98.61 )
ICLR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.96   Max: 99.78
Current: 98.61

11.96
99.78
Revenue Growth (3Y)(%) 15.40
ICLR's Revenue Growth (3Y)(%) is ranked higher than
90% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. ICLR: 15.40 )
ICLR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -14.6   Max: 39.5
Current: 15.4

-14.6
39.5
EBITDA Growth (3Y)(%) 52.70
ICLR's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. ICLR: 52.70 )
ICLR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -19.2   Max: 52.7
Current: 52.7

-19.2
52.7
EPS Growth (3Y)(%) 94.70
ICLR's EPS Growth (3Y)(%) is ranked higher than
98% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. ICLR: 94.70 )
ICLR' s 10-Year EPS Growth (3Y)(%) Range
Min: -34.2   Max: 94.7
Current: 94.7

-34.2
94.7
» ICLR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ICLR Guru Trades in Q2 2014

Ron Baron 1,530,000 sh (+6.99%)
Chuck Royce 210,200 sh (unchged)
Caxton Associates Sold Out
First Eagle Investment Sold Out
Jim Simons 613,600 sh (-13.85%)
» More
Q3 2014

ICLR Guru Trades in Q3 2014

Caxton Associates 50,000 sh (New)
Jim Simons 690,100 sh (+12.47%)
Chuck Royce 210,200 sh (unchged)
Ron Baron 1,515,624 sh (-0.94%)
» More
Q4 2014

ICLR Guru Trades in Q4 2014

Chuck Royce 210,200 sh (unchged)
Caxton Associates Sold Out
Ron Baron 1,469,024 sh (-3.07%)
Jim Simons 524,760 sh (-23.96%)
» More
Q1 2015

ICLR Guru Trades in Q1 2015

Jim Simons 528,260 sh (+0.67%)
Ron Baron 1,469,024 sh (unchged)
Chuck Royce 177,400 sh (-15.60%)
» More
» Details

Insider Trades

Latest Guru Trades with ICLR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Icon PLC

Meridian Funds Comments on Icon PLC - Dec 17, 2014

ICON (ICLR) manages clinical trials for the biotech, pharmaceutical and medical device industries. Our investment in the company materialized when earnings were pressured by an industry slowdown in clinical trials at the same time that ICON was investing in its own capacity expansion. We viewed the slowdown in demand as temporary, caused by the elimination of many duplicative drug development programs. In addition, we thought ICON’s investments in technology positioned the company to gain market share in a growing industry as pharmaceutical customers increasingly outsourced clinical trial work. Strong stock performance in the quarter was driven by revenue and margins coming in above street estimates and a positive management outlook. We continue to hold shares in ICON based on its positioning as a technology leader in the clinical trial industry and the potential to further expand operating margins

From Meridian Funds (Trades, Portfolio)’ Meridian Contrarian Fund 3Q 2014 Commentary.

Check out Meridian Funds latest stock trades

Baron Funds Comments on ICON PLC - Jun 10, 2013

Other purchases in the quarter include ICON plc (ICLR), which is a CRO (Contract Research Organization) providing outsourced drug research to the pharmaceutical industry. We observed from our investment in Covance that the industry is turning, so we purchased a stake in ICON to increase the Fund's exposure to the trend.

From Baron Funds’ first quarter 2013 commentary.
Check out Ron Baron latest stock trades

Top Ranked Articles about Icon PLC

Meridian Funds Comments on Icon PLC
ICON (ICLR) manages clinical trials for the biotech, pharmaceutical and medical device industries. Our investment in the company materialized when earnings were pressured by an industry slowdown in clinical trials at the same time that ICON was investing in its own capacity expansion. We viewed the slowdown in demand as temporary, caused by the elimination of many duplicative drug development programs. In addition, we thought ICON’s investments in technology positioned the company to gain market share in a growing industry as pharmaceutical customers increasingly outsourced clinical trial work. Strong stock performance in the quarter was driven by revenue and margins coming in above street estimates and a positive management outlook. We continue to hold shares in ICON based on its positioning as a technology leader in the clinical trial industry and the potential to further expand operating margins Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.50
ICLR's P/E(ttm) is ranked higher than
95% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ICLR: 21.50 )
ICLR' s 10-Year P/E(ttm) Range
Min: 4.37   Max: 78.79
Current: 21.5

4.37
78.79
Forward P/E 16.21
ICLR's Forward P/E is ranked higher than
94% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ICLR: 16.21 )
N/A
PE(NRI) 21.70
ICLR's PE(NRI) is ranked higher than
95% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ICLR: 21.70 )
ICLR' s 10-Year PE(NRI) Range
Min: 4.36   Max: 78.03
Current: 21.7

4.36
78.03
P/B 4.00
ICLR's P/B is ranked higher than
69% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. ICLR: 4.00 )
ICLR' s 10-Year P/B Range
Min: 0.46   Max: 5.55
Current: 4

0.46
5.55
P/S 2.70
ICLR's P/S is ranked higher than
72% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.41 vs. ICLR: 2.70 )
ICLR' s 10-Year P/S Range
Min: 0.58   Max: 2.9
Current: 2.7

0.58
2.9
PFCF 26.00
ICLR's PFCF is ranked higher than
90% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ICLR: 26.00 )
ICLR' s 10-Year PFCF Range
Min: 5.14   Max: 600.13
Current: 26

5.14
600.13
POCF 21.58
ICLR's POCF is ranked higher than
87% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ICLR: 21.58 )
ICLR' s 10-Year POCF Range
Min: 3.77   Max: 88.35
Current: 21.58

3.77
88.35
EV-to-EBIT 17.06
ICLR's EV-to-EBIT is ranked higher than
90% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ICLR: 17.06 )
ICLR' s 10-Year EV-to-EBIT Range
Min: -10.1   Max: 50.5
Current: 17.06

-10.1
50.5
PEG 1.81
ICLR's PEG is ranked higher than
96% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ICLR: 1.81 )
ICLR' s 10-Year PEG Range
Min: 0.08   Max: 11.49
Current: 1.81

0.08
11.49
Shiller P/E 41.20
ICLR's Shiller P/E is ranked higher than
87% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ICLR: 41.20 )
ICLR' s 10-Year Shiller P/E Range
Min: 6.42   Max: 46.32
Current: 41.2

6.42
46.32
Current Ratio 1.45
ICLR's Current Ratio is ranked higher than
53% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. ICLR: 1.45 )
ICLR' s 10-Year Current Ratio Range
Min: 1.45   Max: 3.61
Current: 1.45

1.45
3.61
Quick Ratio 1.45
ICLR's Quick Ratio is ranked higher than
59% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. ICLR: 1.45 )
ICLR' s 10-Year Quick Ratio Range
Min: 1.45   Max: 3.61
Current: 1.45

1.45
3.61
Days Sales Outstanding 85.64
ICLR's Days Sales Outstanding is ranked higher than
68% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 78.80 vs. ICLR: 85.64 )
ICLR' s 10-Year Days Sales Outstanding Range
Min: 66.88   Max: 179.92
Current: 85.64

66.88
179.92

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.30
ICLR's Price/Tangible Book is ranked higher than
63% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.76 vs. ICLR: 10.30 )
ICLR' s 10-Year Price/Tangible Book Range
Min: 0.64   Max: 7.23
Current: 10.3

0.64
7.23
Price/DCF (Projected) 1.60
ICLR's Price/DCF (Projected) is ranked lower than
55% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ICLR: 1.60 )
ICLR' s 10-Year Price/DCF (Projected) Range
Min: 0.52   Max: 6.85
Current: 1.6

0.52
6.85
Price/Median PS Value 1.80
ICLR's Price/Median PS Value is ranked higher than
59% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. ICLR: 1.80 )
ICLR' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 1.98
Current: 1.8

0.39
1.98
Price/Peter Lynch Fair Value 1.10
ICLR's Price/Peter Lynch Fair Value is ranked higher than
100% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ICLR: 1.10 )
ICLR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.2   Max: 3.2
Current: 1.1

0.2
3.2
Price/Graham Number 3.10
ICLR's Price/Graham Number is ranked higher than
87% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ICLR: 3.10 )
ICLR' s 10-Year Price/Graham Number Range
Min: 0.41   Max: 3.59
Current: 3.1

0.41
3.59
Earnings Yield (Greenblatt) 6.00
ICLR's Earnings Yield (Greenblatt) is ranked higher than
90% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. ICLR: 6.00 )
ICLR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 71.7
Current: 6

2
71.7
Forward Rate of Return (Yacktman) 22.75
ICLR's Forward Rate of Return (Yacktman) is ranked higher than
92% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.27 vs. ICLR: 22.75 )
ICLR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -15.7   Max: 55.6
Current: 22.75

-15.7
55.6

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:0NBW.UK,
Icon PLC was incorporated in 1990. The Company is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The Company organized, operated and assessed its business in two segments, the clinical research segment and the central laboratory segment. The Clinical Research business specializes in the planning, management, execution and analysis of Phase I - IV clinical trials, ranging from small studies to complex, multinational projects. It also conduct various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial Specific clinical research services. The Company provides laboratory services through its central laboratory business, which includes the Company's central laboratories located in Dublin, New York, India, Singapore and China. The Company's areas of operation outside of Ireland include the United States, United Kingdom, France, Germany, Italy, Spain, The Netherlands, Sweden, Belgium, Turkey, Poland, Czech Republic, Lithuania, Latvia, Russia, Ukraine, Hungary, Israel, Romania, Canada, Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China, South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines, Australia, New Zealand, and South Africa. The Company's principal competitors are Covance Inc., PAREXEL International Corporation, Pharmaceutical Product Development Inc., Quintiles Transnational Corporation, inVentiv Health , PRA and INC Research.
» More Articles for ICLR

Headlines

Articles On GuruFocus.com
Probable Gainers Of A European Market Bounce Back Jan 25 2015 
Meridian Funds Comments on Icon PLC Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Baron Funds Comments on ICON PLC Jun 10 2013 
Parexcel: Great Growth but a Tough Business Aug 17 2011 
Weekly Guru Bargains Highlights: SD, CREE, AMLN, ICLR, CVD Nov 07 2010 
ICON publie ses orientations financières pour l’année 2009 et les mises à jour des orientations Jan 09 2009 
Resumen: ICON presenta previsiones financieras para 2009 y actualiza las de 2008 Jan 09 2009 
Samenvatting: ICON publiceert cijfers voor 2009 en werkt cijfers 2008 bij Jan 09 2009 
ICON veröffentlicht Ergebniserwartung für 2009 und aktualisiert Erwartung für 2008 (NASDAQ:ICLR) Jan 09 2009 

More From Other Websites
Can ICON Public Limited (ICLR) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape May 06 2015
Hot No More: Many Top Stocks Hit With Severe Declines Apr 30 2015
ICON Q1 Earnings Top, Revenues Lag; '15 View Updated - Analyst Blog Apr 29 2015
Q1 2015 ICON PLC Earnings Release - Time Not Supplied Apr 28 2015
ICON Reports First Quarter 2015 Apr 28 2015
ICON Reports First Quarter 2015 Apr 28 2015
ICON Launches Electronic Informed Consent Apr 23 2015
ICON Launches Electronic Informed Consent Apr 23 2015
ICON Launches Electronic Informed Consent Apr 23 2015
Cancer Genetics (CGIX) Shows Strength: Stock Gains 5.8% - Tale of the Tape Apr 13 2015
New Book by Industry Thought Leaders Advocates for Re-Engineering Clinical Trials Apr 13 2015
New Book by Industry Thought Leaders Advocates for Re-Engineering Clinical Trials Apr 13 2015
New Book by industry Thought Leaders Advocates for Re-Engineering Clinical Trials Apr 13 2015
MedAssets: A Strong Sell on Tepid View, Estimate Revision - Analyst Blog Apr 09 2015
Air Methods Now a Strong Buy: Is It in Your Portfolio? - Analyst Blog Mar 27 2015
Is ICON Public Limited (ICLR) a Great Growth Stock? - Tale of the Tape Mar 24 2015
ICON and Carnegie Mellon University Collaborate to Evaluate Patient-centric Informed Consent... Mar 23 2015
ICON and Carnegie Mellon University Collaborate to Evaluate Patient-centric Informed Consent... Mar 23 2015
Biogen, Five Other Top Stocks Show No Sign Of Slowing Mar 20 2015
ICON PLC Financials Mar 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK